Entinostat

DB11841InvestigationalSmall molecule

Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic...

Mechanism: Pharmacologically active on Histone deacetylase
Curator reviewed
Formula / weight: C₂₁H₂₀N₄O₃ · 376.416 g/mol (avg)
Code names: BAY 86-5274 · MS 27-275 · MS-275 · MS-275-27 · SNDX-275

Resolves to

Compound

UNII1ZNY4FKK9HCAS209783-80-2ChEMBLCHEMBL27759ChEBI132082PubChem4261

Clinical / RWD

ATCL01XH05

Structure

InChIKeyINVTYAOGFAGBOE-UHFFFAOYSA-NSMILESNC1=CC=CC=C1NC(=O)C1=CC=C(CNC(=O)OCC2=CN=CC=C2)C=C1

Targets

Q13547HDAC1

What you can answer from here — as of September 12, 2025

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

425Drug interactionsStructured to mechanism, not free text

73Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 11 drug categories

14+ReferencesStructured and connected to the statements they support

Which drugs share a target with Entinostat, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account